Login
Companies $CABA
$1.12 +$0.01 (0.9%) After hours
Cabaletta Bio, Inc. logo

Cabaletta Bio, Inc.

cabalettabio.com

What Do They Do?

Develops engineered T cell therapies, led by rese-cel, for patients with autoimmune diseases treated in rheumatology, neurology and dermatology.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −18% (Loss)
vs −$44.9M in Q3 FY2025
  • Nov 9, 2026 Cabaletta presented new Phase 1/2 rese-cel data across autoimmune diseases The company reported one-year dermatomyositis responses and lupus nephritis remission findings, and said it is enrolling a registrational systemic sclerosis cohort.

From two strategies to CARTA focus The older report described two approaches: CARTA, which depletes all B cells, and CAART, which targets disease-causing B cells. The latest report centers its development program on rese-cel and the CARTA approach.

Who Do They Compete With?

Competes with Novartis Pharmaceuticals, Gilead Sciences, Bristol Myers Squibb, Johnson and Johnson, Legend Biotech, and Autolus

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support